Safflower extract: A novel renal fibrosis antagonist that functions by suppressing autocrine TGF-Beta

Journal of Cellular Biochemistry

Volumn 104, Issue 3, 2008, Pages 908-919

  Yang, Yu Lin ^a   Chang, Shan Yu ^a   Teng, Hsiang Chun ^a   Liu, Yi Shiuan ^a   Lee, Tao Chen ^b   Chuang, Lea Yea ^c   Guh, Jinn Yuh ^c   Chang, Fang Rong ^c   Liao, Tung Nan ^a   Huang, Jau Shyang ^a   Yeh, Jeng Hsien ^d   Chang, Wen Teng ^a   Hung, Min Yuan ^a   Wang, Ching Jen ^b   Chiang, Tai An ^a   Hung, Chien Ya ^a   Hung, Tsung Jen ^e  

^a CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e Chest Hospital   (Taiwan)

Author keywords

Chinese herb; Fibronectin; Fibrosis; Safflower; Smad; TGF

Indexed keywords

3 HYDROXYBUTYRIC ACID; CAPTOPRIL; FIBRONECTIN; SAFFLOWER EXTRACT; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; URETER OBSTRUCTION; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRONECTINS; FIBROSIS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; MALE; MEDICINE, CHINESE TRADITIONAL; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

CARTHAMUS TINCTORIUS; RATTUS;

EID: 45149132895     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21676     Document Type: Article

References (39)

1. Bolte MR, Hess BW, Means WJ, Moss GE, Rule DC. 2002. Feeding lambs high-oleate or high-linoleate safflower seeds differentially influences carcass fatty acid composition. J Anim Sci 80(3):609-616.
2. Border WA, Noble NA. 1994. Transforming growth factor beta in tissue fibrosis. N Engl J Med 331(19):1286-1292.
3. Cassileth BR. 1999. Evaluating complimentary and alternative therapies for cancer patients. CA Cancer J Clin 49:362-375.
4. Chuang LY, Guh JY, Liu SF, Hung MY, Liao TN, Chiang TA, Huang JS, Huang YL, Lin CF, Yang YL. 2003. Regulation of type II transforming-growth-factor-beta receptors by protein kinase C iota. Biochem J 375(Pt 2):385-393.
5. Eddy AA. 1996. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7:2495-2508.
6. Eddy AA. 2000. Molecular basis of renal fibrosis. Pediatr Nephrol 15:290-301.
7. Guh JY, Yang ML, Yang YL, Chang CC, Chuang LY. 1996. Captopril reverses high-glucose-induced growth effects on LLC-PK1 cells partly by decreasing transforming growth factor-beta receptor protein expressions. J Am Soc Nephrol 7(8):1207-1215.
8. Guh JY, Chuang TD, Chen HC, Hung WC, Lai YH, Shin SJ, Chuang LY. 2003. Beta-hydroxybutyrate-induced growth inhibition and collagen production in HK-2 cells are dependent on TGF-beta and Smad3. Kidney Int 64(6):2041-2051.
9. Hostetter TH. 1991. Diabetic nephropathy. In: Brenner BM, Rector RC, editors. The kidney 4th edition. Philadelphia: WB Saunders. pp 1695-1727.
10. Huang JS, Chuang LY, Guh JY, Chen CJ, Yang YL, Chiang TA, Hung MY, Liao TN. 2005. Effect of nitric oxide-cGMP-dependent protein kinase activation on advanced glycation end-product-induced proliferation in renal fibroblasts. J Am Soc Nephrol 16(8):2318-2329.
11. Isaka Y, Akagi Y, Ando Y, Tsujie M, Sudo T, Ohno N, Border WA, Noble NA, Kaneda Y, Hori M, Imai E. 1999. Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 55:465-475.
12. Isaka Y, Tsujie M, Ando Y, Nakamura H, Kaneda Y, Imai E, Hori M. 2000. Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int 58:1885-1892.
13. Kanehira T, Takekoshi S, Nagata H, Matsuzaki K, Kambayashi Y, Osamura RY, Homma T. 2003. A novel and potent biological antioxidant, Kinobeon A, from cell culture of safflower. Life Sci 74(1):87-97.
14. Kaneto H, Ohtani H, Fukuzaki A, Ishidoya S, Takeda A, Ogata Y, Nagura H, Orikasa S. 1999. Increased expression of TGF-beta 1 but not of its receptors contributes to human obstructive nephropathy. Kidney Int 56:2137-2146.
15. Kim HM, An CS, Jung KY, Choo YK, Park JK, Nam SY. 1999. Rehmannia Glutinosa inhibits tumor necrosis factor-alpha and interleukin-1 secretion from mouse astrocytes. Pharmacol Res 40:171-176.
16. Klahr S, Ichikawa I. 1988. The progression of renal disease. N Engl J Med 318:1657-1666.
17. Klahr S, Morrissey J. 1997. Comparative study of ACE inhibitors and angiotensin II receptor antagonists in interstitial scarring. Kidney Int Suppl 63:S111-S114.
18. Klahr S, Morrissey J. 2002. Obstructive nephropathy and renal fibrosis. Am J Physiol Ren Physiol 283:F861-LF875.
19. Lee JY, Chang EJ, Kim HJ, Park JH, Choi SW. 2002. Antioxidative flavonoids from leaves of Carthamus tinctorius. Arch Pharm Res 25(3):313-319.
20. Lee CI, Guh JY, Chen HC, Lin KH, Yang YL, Hung WC, Lai YH, Chuang LY. 2004. Leptin and connective tissue growth factor in advanced glycation end-product-induced effects in NRK-49F cells. J Cell Biochem 93(5):940-950.
21. Lee CI, Guh JY, Chen HC, Hung WC, Yang YL, Chuang LY. 2005. Advanced glycation end-product-induced mitogenesis and collagen production are dependent on angiotensin II and connective tissue growth factor in NRK-49F cells. J Cell Biochem 95(2):281-292.
22. Li Y, Che Q. 1998. Studies on chemical components of Carthamus tinctorius petals. Yao Xue Xue Bao 33(8):626-628.
23. Liu HC, Liao TN, Lee TC, Chuang LY, Guh JY, Liu SF, Hu MS, Yang YL, Lin SH, Hung MY, Huang JS, Hung TJ, Chen CD, Chiang TA, Chan JY, Chen SY, Yang YL. 2006. Albumin induces cellular fibrosis by upregulating transforming growth factor-beta ligand and its receptors in renal distal tubule cells. J Cell Biochem 97(5):956-968.
24. Ma LJ, Jha S, Ling H, Pozzi A, Ledbetter S, Fogo AB. 2004. Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int 65:106-115.
25. Massague J. 2000. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1:169-178.
26. Miyajima A, Chen J, Lawrence C, Ledbetter S, Soslow RA, Stern J, Jha S, Pigato J, Lemer ML, Poppas DP, Vaughan ED, Felsen D. 2000. Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 58:2301-2313.
27. Nakamura M, Tanaka H, Hattori Y, Watanabe M. 1973. Biological effects of autoxidized safflower oils. Lipids 8(10):566-572.
28. Placier S, Flamant M, Boffa JJ, Dussaule JC, Chatziantoniou C. 2006. Renal hemodynamics and development of renal fibrotic lesions during hypertension. Arch Mal Coeur Vaiss 99(7-8):697-700.
29. Rastaldi MP. 2006. Epithelial-mesenchymal transition and its implications for the development of renal tubulointerstitial fibrosis. J Nephrol 19(4):407-412.
30. Romano C, Price M, Bai HY, Olney JW. 1993. Neuroprotectants in Honghua: Glucose attenuates retinal ischemic damage. Invest Ophthalmol Vis Sci 34(1):72-80.
31. Shi XC. 1983. Chinese-english terminology of traditional Chinese medicine. China: Human Science Publishing Co. pp 71-98.
32. Sugiyama H, Kobayashi M, Wang DH, Sunami R, Maeshima Y, Yamasaki Y, Masuoka N, Kira S, Makino H. 2005. Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. Nephrol Dial Transplant 20(12):2670-2680.
33. Takii T, Kawashima S, Chiba T, Hayashi H, Hayashi M, Hiroma H, Kimura H, Inukai Y, Shibata Y, Nagatsu A, Sakakibara J, Oomoto Y, Hirose K, Onozaki K. 2003. Multiple mechanisms involved in the inhibition of proinflammatory cytokine production from human monocytes by N-(p-coumaroyl) serotonin and its derivatives. Int Immunopharmacol 3(2):273-277.
34. Wolf G, Ziyadeh FN. 1999. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56(2):393-405.
35. Yan HD, Li XZ, Xie JM, Li M. 2007. Effects of advanced glycation end products on renal fibrosis and oxidative stress in cultured NRK-49F cells. Chin Med J (Engl) 120(9):787-793.
36. Yang YL, Guh JY, Yang ML, Lai YH, Tsai JH, Hung WC, Chang CC, Chuang LY. 1998. Interaction between high glucose and TGF-beta in cell cycle protein regulations in MDCK cells. J Am Soc Nephrol 9(2):182-193.
37. Yang YL, Chuang LY, Guh JY, Liu SF, Hung MY, Liao TN, Huang YL. 2004. Thrombospondin-1 mediates distal tubule hypertrophy induced by glycated albumin. Biochem J 379(Pt 1):89-97.
38. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG, Seidel K. 1995. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 47:935-944.
39. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K. 2000. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci 97:8015-8020.